Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.
Tronde, Ann ; Gillen, Michael ; Borgström, Lars ; Lötvall, Jan and Ankerst, Jaro LU
(2008)
In Journal of Clinical Pharmacology
48(11).
p.1300-1308
- Abstract
- In 3 open-label studies, the systemic bioavailability of budesonide and formoterol administered via pressurized metered-dose inhaler (pMDI) or dry powder inhaler (DPI) formulations was evaluated in asthma (24 children, 55 adults) or chronic obstructive pulmonary disease (COPD; n = 26) patients. Treatments were administered at doses high enough to estimate pharmacokinetic parameters reliably. Two of the studies included an experimental budesonide pMDI formulation. In study 1 (asthma, adults), budesonide area under the curve (AUC) was 32% and 31% lower and maximal budesonide concentration (C(max)) 45% and 56% lower after budesonide/formoterol pMDI and budesonide pMDI versus budesonide DPI. Formoterol AUC and C(max) were 13% and 39% lower... (More)
- In 3 open-label studies, the systemic bioavailability of budesonide and formoterol administered via pressurized metered-dose inhaler (pMDI) or dry powder inhaler (DPI) formulations was evaluated in asthma (24 children, 55 adults) or chronic obstructive pulmonary disease (COPD; n = 26) patients. Treatments were administered at doses high enough to estimate pharmacokinetic parameters reliably. Two of the studies included an experimental budesonide pMDI formulation. In study 1 (asthma, adults), budesonide area under the curve (AUC) was 32% and 31% lower and maximal budesonide concentration (C(max)) 45% and 56% lower after budesonide/formoterol pMDI and budesonide pMDI versus budesonide DPI. Formoterol AUC and C(max) were 13% and 39% lower after budesonide/formoterol pMDI versus formoterol DPI. In study 2 (asthma, children), budesonide AUC and C(max) were 27% and 41% lower after budesonide/formoterol pMDI versus budesonide DPI + formoterol DPI. In study 3 (COPD/asthma, adults), budesonide AUC and C(max) were similar and formoterol AUC and C(max) 18% and 22% greater after budesonide/formoterol pMDI versus budesonide pMDI + formoterol DPI (COPD). Budesonide and formoterol AUC were 12% and 15% higher in COPD versus asthma patients. In conclusion, systemic exposure generally is similar or lower with budesonide/formoterol pMDI versus combination therapy via separate DPIs or monotherapy and comparable between asthma and COPD patients. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1271895
- author
- Tronde, Ann
; Gillen, Michael
; Borgström, Lars
; Lötvall, Jan
and Ankerst, Jaro
LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Pharmacology
- volume
- 48
- issue
- 11
- pages
- 1300 - 1308
- publisher
- SAGE Publications
- external identifiers
-
- wos:000260386200005
- pmid:18974284
- scopus:54049119717
- pmid:18974284
- ISSN
- 0091-2700
- DOI
- 10.1177/0091270008322122
- language
- English
- LU publication?
- yes
- id
- 43d122d8-8abf-4327-a9e5-a4d7b573eede (old id 1271895)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/18974284?dopt=Abstract
- date added to LUP
- 2016-04-01 13:02:20
- date last changed
- 2024-01-09 06:34:00
@article{43d122d8-8abf-4327-a9e5-a4d7b573eede,
abstract = {{In 3 open-label studies, the systemic bioavailability of budesonide and formoterol administered via pressurized metered-dose inhaler (pMDI) or dry powder inhaler (DPI) formulations was evaluated in asthma (24 children, 55 adults) or chronic obstructive pulmonary disease (COPD; n = 26) patients. Treatments were administered at doses high enough to estimate pharmacokinetic parameters reliably. Two of the studies included an experimental budesonide pMDI formulation. In study 1 (asthma, adults), budesonide area under the curve (AUC) was 32% and 31% lower and maximal budesonide concentration (C(max)) 45% and 56% lower after budesonide/formoterol pMDI and budesonide pMDI versus budesonide DPI. Formoterol AUC and C(max) were 13% and 39% lower after budesonide/formoterol pMDI versus formoterol DPI. In study 2 (asthma, children), budesonide AUC and C(max) were 27% and 41% lower after budesonide/formoterol pMDI versus budesonide DPI + formoterol DPI. In study 3 (COPD/asthma, adults), budesonide AUC and C(max) were similar and formoterol AUC and C(max) 18% and 22% greater after budesonide/formoterol pMDI versus budesonide pMDI + formoterol DPI (COPD). Budesonide and formoterol AUC were 12% and 15% higher in COPD versus asthma patients. In conclusion, systemic exposure generally is similar or lower with budesonide/formoterol pMDI versus combination therapy via separate DPIs or monotherapy and comparable between asthma and COPD patients.}},
author = {{Tronde, Ann and Gillen, Michael and Borgström, Lars and Lötvall, Jan and Ankerst, Jaro}},
issn = {{0091-2700}},
language = {{eng}},
number = {{11}},
pages = {{1300--1308}},
publisher = {{SAGE Publications}},
series = {{Journal of Clinical Pharmacology}},
title = {{Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.}},
url = {{http://dx.doi.org/10.1177/0091270008322122}},
doi = {{10.1177/0091270008322122}},
volume = {{48}},
year = {{2008}},
}